378 related articles for article (PubMed ID: 32483906)
1. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
[TBL] [Abstract][Full Text] [Related]
2. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy.
Pascart T; Latourte A; Flipo RM; Chalès G; Coblentz-Baumann L; Cohen-Solal A; Ea HK; Grichy J; Letavernier E; Lioté F; Ottaviani S; Sigwalt P; Vandecandelaere G; Richette P; Bardin T
Joint Bone Spine; 2020 Oct; 87(5):395-404. PubMed ID: 32422338
[TBL] [Abstract][Full Text] [Related]
3. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
4. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
5. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Corbett EJM; Pentony P; McGill NW
Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
Pui K; Gow PJ; Dalbeth N
J Rheumatol; 2013 Jun; 40(6):872-6. PubMed ID: 23457380
[TBL] [Abstract][Full Text] [Related]
7. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
[TBL] [Abstract][Full Text] [Related]
8. Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long-Term Urate-Lowering Therapy in the American College of Rheumatology RISE Registry.
Hammam N; Li J; Kay J; Izadi Z; Yazdany J; Schmajuk G
Arthritis Care Res (Hoboken); 2023 Jul; 75(7):1544-1552. PubMed ID: 36039961
[TBL] [Abstract][Full Text] [Related]
9. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Arthritis Res Ther; 2017 Dec; 19(1):283. PubMed ID: 29268756
[TBL] [Abstract][Full Text] [Related]
10. Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care.
Latif ZP; Nakafero G; Jenkins W; Doherty M; Abhishek A
Joint Bone Spine; 2019 May; 86(3):357-362. PubMed ID: 30394337
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout.
Coleman GB; Dalbeth N; Frampton C; Haslett J; Drake J; Su I; Horne AM; Stamp LK
J Rheumatol; 2022 Dec; 49(12):1372-1378. PubMed ID: 35777814
[TBL] [Abstract][Full Text] [Related]
12. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
[TBL] [Abstract][Full Text] [Related]
13. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Feng X; Li Y; Gao W
Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of tart cherry concentrate dose on serum urate in people with gout.
Stamp LK; Chapman P; Frampton C; Duffull SB; Drake J; Zhang Y; Neogi T
Rheumatology (Oxford); 2020 Sep; 59(9):2374-2380. PubMed ID: 31891407
[TBL] [Abstract][Full Text] [Related]
15. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
[TBL] [Abstract][Full Text] [Related]
16. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
Stamp LK; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Chapman PT
Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
[TBL] [Abstract][Full Text] [Related]
17. Burden and management of gout in a multi-ethnic Asian cohort.
Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
[TBL] [Abstract][Full Text] [Related]
18. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
[TBL] [Abstract][Full Text] [Related]
19. Blood glucose fluctuations detected by continuous glucose monitoring system in gout patients with normal glucose tolerance and the effect of urate-lowering therapy.
Mu Z; Wang J; Wang W; Lv W; Chen Y; Wang F; Zhao Y; Dong B; Wang Y; Wang Z
Int J Rheum Dis; 2020 Aug; 23(9):1145-1151. PubMed ID: 32483927
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
